Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Animal studies revealed that VK supplementation dose-dependently upregulated plasma cGas6; stimulated the protein expression of cGas6, PI3K, pAKT, and GLUT4 in skeletal muscle; and reduced hyperglycemia in HFD-fed T2D mice.
|
31583710 |
2020 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Solute carrier family 2 member 4- (SLC2A4-) retinol binding protein-4- (RBP4-) phosphoenolpyruvate carboxykinase 1 (PCK1)/phosphoinositide 3-kinase (PI3K) is an adipocyte derived "signalling pathway" that may contribute to the pathogenesis of type 2 diabetes mellitus (T2DM).
|
30805369 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Expression of the glucose transporter GLUT4, encoded by Slc2a4 gene, is reduced in both type 1 and type 2 diabetes (T1D and T2D), contributing to glycemic impairment.
|
30528377 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
In the late 1980s, when GLUT4, the major insulin-regulated glucose transporter, was identified, my lab observed that it was downregulated in adipocytes but not in skeletal muscle in insulin-resistant states, such as obesity and type 2 diabetes, in humans and rodents.
|
30573674 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
The present study demonstrates that liquorice flavonoid oil (LFO) improves type 2 diabetes mellitus through GLUT4 translocation to the plasma membrane by activating both the adenosine monophosphate-activated protein kinase (AMPK) pathway and Akt pathway in muscle of KK-A<sup>y</sup> mice.
|
30304967 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Muscle expression of HKII and SLC2A4 and hexokinase II protein content were reduced in patients with T2D.
|
31135885 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The aim of the present study was to determine the effect of pomegranate seed oil (PSO) on the GLUT-4 gene expression and glycemic control in obese people with T2DM.
|
30945297 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
CI = confidence interval; GLUT4 = glucose transporter 4; HOMA-IR = homeostatic model assessment for insulin resistance; HR = hazard ratio; LATS = Latin American Thyroid Society; MetS = metabolic syndrome; OR = odds ratio; ScH = subclinical hypothyroidism; T2DM = type 2 diabetes mellitus; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid-stimulating hormone.
|
30742573 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
However, it is currently unknown how insulin signaling targeting WNK1 regulates GLUT4 trafficking in skeletal muscle, and whether this regulation is perturbed in T2D.
|
30410865 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
The expressions of phosphatidylinositol-3-kinase (PI-3K), protein kinase B (Akt), glucose transporters-4 (GLUT4) Mrna, and p-PI-3K, p-Akt, GLUT4 protein involved in the PI-3K/Akt signaling pathway of T2DM were markedly up-regulated.
|
30210342 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
These findings unraveled a novel mechanism for IR that involves repression of GLUT4 by miR-17 and suggested miR-17 as a potential molecular target for the development of new therapeutic approaches for the treatment of T2DM.
|
30170066 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
This study produced new evidence that intermittent exposure to mild hypoxia (0.15 FiO2) for four weeks resulted in normalisation of FBG, improvement in whole body insulin sensitivity, and a significant increase of GLUT4 translocation in the skeletal muscle, that were similar to the effects of exercise intervention during the same time period, in mice with diet-induced type 2 diabetes.
|
30199540 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Glucose transporter 4 (GLUT4) plays a key role in the pathophysiology of type 2 diabetes.
|
29271848 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Exercise was protective against paternal HF-diet-induced insulin resistance by increasing the expression of insulin signaling (GLUT4, IRS1 and PI3K) markers in skeletal muscle resulting in normal T2D risk.
|
29669306 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study show that DOPE retains cell surface GLUT4 by suppressing PKCα-driven endocytic internalization of GLUT4, to enhance glucose uptake into cells and restrict an increase in the blood glucose levels after glucose loading in type 2 DM.
|
29723855 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Administrations of MgSO<sub>4</sub> or insulin in Type 2 diabetes mellitus animals increase GLUT4 gene and protein expression.
|
29869808 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Glucose transporter 4 (GLUT4) is one of the main proteins that transport blood glucose into the cells and is a target in the treatment of T2DM.
|
30524480 |
2018 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
The blood glucose level of DM_V rats was significantly reduced, while the glucose transporter 4 (GLUT4) expression and blood microcirculation of DM_V rats were significantly enhanced in comparison to those of DM rats.
|
28912573 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
The downregulation of phosphorylation-AKT (p-AKT) and glucose transporter-4 (GLUT4) in skeletal muscle of T2DM rats was restored and abnormal pathological changes in pancreas tissues were also improved.
|
28904560 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Further, metformin mitigated T2DM-induced decrease in hepatic phosphorylated Akt and GLUT-4 translocation in the animals.
|
28142314 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Defects in translocation of the glucose transporter GLUT4 are associated with peripheral insulin resistance, preclinical diabetes, and progression to type 2 diabetes.
|
28972183 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Molecular mechanism studies demonstrated impairment of signaling cascade, IRS1/PI3K/Akt/AMPK/p 38/GLUT4, in glucose metabolism in the skeletal muscle of T2D rats.
|
28533752 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
Biomarker
|
disease |
BEFREE |
Moreover, the expression levels of InsR, IRS-2, Akt and GLUT4 in the MFP90 group significantly increased relative to that of the T2DM group.
|
28163112 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
In patients with type 2 diabetes, the expression levels of glucose transporter 4 (GLUT‑4) in skeletal muscles are significantly decreased, indicating decreased glucose‑processing ability.
|
28944847 |
2017 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Thus, our results suggest that downregulation of GLUT4 in skeletal muscle may be associated with insulin resistance in chronic kidney disease and could lead to type 2 diabetes in predisposed animals.
|
28459862 |
2017 |